0 Items
Select Page

Canine Coronavirus

Canine coronavirus (CCoV) is an alphacoronavirus which infects dogs and is closely related to enteric coronaviruses of cats and pigs. CCoV is emerging as a significant pathogen in veterinary medicine, and is becoming an important cause of disease. Traditionally it has caused mild gastro-intestinal clinical signs, but there are increasing reports of lethal CCoV infections in dogs.

Canine Coronavirus Background

Coronaviruses are enveloped, single-stranded, positive-sense RNA viruses that infect humans and a wide variety of animal species. Canine coronavirus (CCoV) was first isolated and recognised as a pathogen of dogs in 1971, during an outbreak of gastroenteritis in military dogs (Binn et al., 1974). CCoV are large, enveloped, positive-stranded RNA viruses. Their particles are enveloped and are composed of four major structural proteins; spike (S), envelope (E), membrane (M), and nucleocapsid (N). The association of the N protein with the genomic RNA forms the helical nucleocapsid that is surrounded by an icosahedral structure composed of the viral M protein. The virus enters cells upon receptor binding and membrane fusion (mediated via the viral S protein) and replicates within the cytoplasm. It then exits the cell via exocytosis (Licitra et al. 2014).

There are two known types of canine coronaviruses; CCoV is a member of the alphacoronavirus genus, and the more recently identified canine respiratory coronavirus (CRCoV) is a member of the betacoronavirus genus. CCoV is closely related to transmissible gastroenteritis virus (TGEV) of pigs, ferret coronavirus and feline coronavirus (FCoV); whereas CRCoV is more closely related to bovine coronavirus. CCoV contains two distinct serotypes, type I and type II which have markedly different spike proteins. It has been proposed that type I CCoVs and FCoVs evolved from a common ancestral virus, and that the canine and feline type II lineages arose from multiple recombination events with an unidentified genetic source (Buonavoglia et al., 2006; Licitra et al. 2014).

CCoV is transmitted by the fecal-oral route and infection in dogs is usually restricted to the enteric tract with a self-limiting infection which generally produces only mild or asymptomatic forms of enteritis. However, more recently a pantropic, highly pathogenic variant of CCoV type II has been identified (Buonavoglia et al., 2006). Canine enteric coronavirus (CCoV) is an alphacoronavirus infecting dogs that is closely related to enteric coronaviruses of cats and pigs. While CCoV has traditionally caused mild gastro-intestinal clinical signs, there are increasing reports of lethal CCoV infections in dogs. CCoV infection can be fatal, particularly in puppies co-infected with other pathogens such as canine parvovirus. However, an increasing number of reports of infections by highly virulent CCoVs (pantropic CCoV) have been reported in puppies without apparent coinfections (Licitra et al. 2014).

Inactivated and modified-live virus vaccines are commercially available, but provide incomplete protection as they reduce, but do not eliminate CCoV replication in the intestinal tract. There are no anti-viral drugs available for treatment of CCoV infection.



  • Binn et al. (1974). Recovery and characterization of a coronavirus from military dogs with diarrhea. Proc Annu Meet U S Anim Health Assoc. (78):359-66.
  • Buonavoglia et al. (2006). Canine Coronavirus Highly Pathogenic for Dogs. Emerg Infect Dis. 12(3): 492–494.
  • Licitra et al. (2014). Canine Enteric Coronaviruses: Emerging Viral Pathogens with Distinct Recombinant Spike Proteins. Viruses. 6(8): 3363–3376.

Canine Coronavirus Antigens

We are please to offer an inactivated and purified canine coronavirus. This antigen is suitable for use in assay development, vaccine research and as antigens for the preparation of CCoV-specific antibodies.

Canine Coronavirus Antibodies

We offer a pair of monoclonal antibodies that are specific to canine coronavirus nucleoprotein and are suitable for use in immunoassay development and vaccine research.


Check out our FAQ section for answers to the most frequently asked questions about our website and company.

A Q&A with David Flavell of Leukaemia Busters

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

The Bumpy Road to a Cytomegalovirus Vaccine

The development of a cytomegalovirus vaccine has been 50 years in the making. Are there any technologies in the pipeline that could prompt a breakthrough? This article was originally posted online at The Medicine Maker, a Texere publication.To say that...

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

1 + 5 =

Live Customer Feedback

Join our mailing list

* indicates required